In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

However, in December 2024, the Food and Drug Administration (FDA) approved a new version of nivolumab (Opdivo Qvantig) for use as a subcutaneous injection. This means a person can receive the drug ...

The 12–month study involved 233 subjects, including 217 patients under the age of 18. Only 14% of the patients who received subcutaneous injections of immunoglobulin missed work or study due to ...

Subcutaneous Injections 101 When it comes to managing diabetes, insulin injections play a vital role. Many people are unaware that the primary method of administering insulin is subcutaneously – ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year.

VYVGART Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients can self-inject ...

Types of Self-Injections There are two types of self-injections: intramuscular (IM) injections and subcutaneous (SubQ) injections. An intramuscular injection is a way of injecting medication deep into ...

For permission requests, please contact NEJM Reprints at [email protected] ...

A 30 year old woman with a history of depression and previous suicide attempts was brought to the emergency department in coma. She had injected herself with cyanide subcutaneously and had severe ...

Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. The single-dose ...

Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As ...